Why Is SUMMIT THERAPEUTICS (SMMT) Stock Up Today?

Why SMMT stock is up today

SMMT stock rose 6.64% to $18.72 on Friday, driven by positive trial results for its experimental drug ivonescimab in a Phase 3 lung cancer study. The compound outperformed Keytruda, reducing the risk of death by 27% in non-small cell lung cancer patients. The data, released by Summit’s partner, has sparked investor interest and fueled a sharp intraday rally.

What Happened

Summit Therapeutics Inc. filed an 8-K on Friday disclosing other events and financial statements. The most impactful development came from its partner, which announced updated data from the Phase III HARMONi-2 trial. Ivonescimab monotherapy showed a statistically significant improvement in overall survival compared to pembrolizumab monotherapy. The trial, conducted in China, demonstrated that ivonescimab cut death risk by 27% versus Keytruda, a major milestone for the company’s lead cancer therapy. The stock opened with a 5.1% gap up and climbed further throughout the session, reaching a high of $18.79 before settling near $18.69.

What The Data Shows

The stock has surged 27.0% over the past eight sessions, climbing from $14.17 to $18.00. On Friday alone, it reached a new 52-week high, marking eight such highs on the day. The intraday volume of 0.8 million shares, while below the 3-month average, reflects concentrated buying interest. The stock remains within its 52-week range of $12.07 to $29.23, though it is still unprofitable with a TTM EPS of -1.12 and negative revenue growth of 100.0% TTM.

What To Watch

Summit Therapeutics has no upcoming earnings date disclosed. Investors should monitor the breadth of coverage and further data releases from its Phase III trials, as well as potential regulatory developments or partnership updates.